Summary of Significant Accounting Policies (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2026 |
Dec. 31, 2025 |
| Summary of Significant Accounting Policies [Abstract] |
|
|
| Schedule of Net Loss Attributable to Common Stockholders |
The following tables reconcile net loss to net loss attributable to common stockholders:
| | | For the Three Months Ended
June 30, | | | | | 2026 | | | 2025 | | | | | | | | | | | Net loss | | $ | 3,772,008 | | | $ | 655,943 | | | Series B cumulative dividends | | | 126,037 | | | | 498,670 | | | Net loss attributable to common stockholders | | $ | 3,898,045 | | | $ | 1,154,613 | | | | | For the Six Months Ended
June 30, | | | | | 2026 | | | 2025 | | | | | | | | | | | Net loss | | $ | 4,695,299 | | | $ | 1,195,560 | | | Series B cumulative dividends | | | 619,228 | | | | 991,860 | | | Net loss attributable to common stockholders | | $ | 5,314,527 | | | $ | 2,187,420 | |
|
For the year ended December 31, 2025: | Net loss | | $ | (3,847,637 | ) | | Series B cumulative dividends (undeclared) | | | (2,000,160 | ) | | Net loss attributable to common stockholders | | $ | (5,847,797 | ) |
|
| Schedule of Computation of Diluted Net Loss Per Common Share |
The following potential dilutive securities were excluded from the computation of diluted net loss per common share because their effect would have been anti-dilutive: | | | June 30,
2026 | | | June 30,
2025 | | | | | | | | | | | Series A convertible preferred shares | | | — | | | | 111,358 | | | Series B convertible preferred shares including the cumulative dividends | | | — | | | | 546,469 | | | Common stock warrants | | | 30,076 | | | | 26,697 | | | Stock options | | | 126,988 | | | | 64,148 | | | Total potentially dilutive shares | | | 157,064 | | | | 748,672 | |
|
The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: | | | December 31, | | | | | 2025 | | | 2024 | | | Series A convertible preferred shares | | | 111,358 | | | | 111,358 | | | Series B convertible preferred shares including the cumulative dividends | | | 562,688 | | | | 530,509 | | | Common stock warrants | | | 26,697 | | | | 33,455 | | | Stock options | | | 126,988 | | | | 70,971 | | | Total potentially dilutive shares | | | 827,731 | | | | 746,293 | |
|
| Schedule of Restatement on the Company’s Statement of Operations |
|
The impact of the restatement on the Company’s statement of operations for the year ended December 31, 2024 was as follows: | | | As
Previously
Reported | | | Adjustment | | | As
Restated | | | Net loss | | $ | (4,855,405 | ) | | $ | — | | | $ | (4,855,405 | ) | | Series B cumulative dividends | | | — | | | | (2,000,160 | ) | | | (2,000,160 | ) | | Net loss attributable to common stockholders | | $ | (4,855,405 | ) | | | (2,000,160 | ) | | $ | (6,855,565 | ) | | Basic and diluted net loss per share | | $ | (7.03 | ) | | $ | (2.89 | ) | | $ | (9.92 | ) |
|